Boston Scientific insider files Form 4: option grant and 50,000-share sale detailed
Rhea-AI Filing Summary
Joseph Michael Fitzgerald, EVP & Group President, Cardiology at Boston Scientific (BSX), reported option activity and open-market sales on 10/01/2025. The filing shows a grant of a stock option to purchase 50,000 shares with an exercise price of $26.15; the option vests in four equal annual installments and the reported exercisable/expiration schedule lists an expiration of 12/01/2027. On the same date the reporting person sold 8,245 shares at a weighted average price of $98.9063 and 41,755 shares at a weighted average price of $98.3797, totaling 50,000 shares sold. The transactions were effected under a pre-established Rule 10b5-1 trading plan adopted 02/27/2025. The report disclaims beneficial ownership of 5,234 shares held by the reporting person’s child. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Positive
- Transactions disclosed explicitly and promptly via Form 4, including option grant, sales and 10b5-1 plan adoption
- Use of a pre-established Rule 10b5-1 trading plan (adopted 02/27/2025) to effect sales, which is documented in the filing
Negative
- Insider sold 50,000 shares on 10/01/2025 (8,245 at weighted average $98.9063 and 41,755 at weighted average $98.3797), reducing direct holdings
- Large gross proceeds from sales (implied by volumes and prices disclosed) represent a material disposition of insider-held shares on that date
Insights
TL;DR: Insider exercised options and sold 50,000 shares under a pre-established 10b5-1 plan; sale proceeds reflect prices near $98.4–$98.9.
The transactions combine an exercise/grant event (50,000-share option at $26.15) and contemporaneous market sales of 50,000 shares at weighted average prices of $98.9063 and $98.3797. The use of a 10b5-1 plan (adopted 02/27/2025) signals pre-planned disposition rather than opportunistic trading. From a capital-impact perspective, the option grant with multi-year vesting maintains alignment with long-term compensation structures while the sales materially reduced the reporting person’s direct holdings by the number of shares sold. These are routine, reportable insider transactions without additional corporate disclosures in this filing.
TL;DR: Filing shows compliant Section 16 reporting: option grant details, Rule 10b5-1 execution, and explicit disclaimer of child-held shares.
The Form 4 provides clear compliance signals: it documents the grant terms (exercise price $26.15, vesting in four equal annual installments, expiration 12/01/2027), lists sales executed pursuant to a 10b5-1 plan adopted 02/27/2025, and includes an express disclaimer regarding 5,234 shares held by the reporting person’s child. The signature by an attorney-in-fact is included. These elements reflect standard governance and disclosure practices for insider equity transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
| Exercise | Common Stock | 50,000 | $26.15 | $1.31M |
| Sale | Common Stock | 8,245 | $98.9063 | $815K |
| Sale | Common Stock | 41,755 | $98.3797 | $4.11M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 27, 2025. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $98.86 to $98.96, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $97.86 to $98.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.
